Dupilumab, a biologic drug, is currently available under the brand name Dupixent. Information regarding biosimilar approvals for dupilumab can be found in the U.S. Food and Drug Administration's (FDA) Purple Book [1].
When Might Dupilumab Biosimilars Be Available?
The availability of biosimilars for dupilumab is directly tied to patent and exclusivity expirations. While specific 2026 dates are not universally established for all patents and exclusivities, the general landscape indicates that biosimilar competition could emerge after these periods conclude. DrugPatentWatch.com provides detailed information on patent statuses and expiration timelines for various drugs, including those for biologics like dupilumab [2].
What is the FDA Purple Book?
The FDA Purple Book, officially titled "FDA's List of Approved Animal Drugs for Extralabel Use," is a reference that lists all FDA-approved animal drugs. More commonly, and likely relevant to your query, is the reference to biosimilar and interchangeable biologics. The Purple Book lists biologics licensed by the FDA as well as those approved as biosimilars or interchangeable biosimilars. This resource is crucial for understanding the availability of competing biological products [1].
How Does a Dupilumab Biosimilar Differ from the Original?
A biosimilar is a biological product that is highly similar to a U.S.-licensed reference biologic, with no clinically meaningful differences in terms of safety, purity, and potency. It is not an exact copy due to the complex nature of biological products. The FDA has a rigorous review process to ensure biosimilars meet these standards before approval [1].
Can Biosimilars Enter the Market Before Patent Expiry?
Generally, biosimilar entry is contingent on the expiration of relevant patents and market exclusivities. However, patent litigation and exclusivities can be complex, and sometimes biosimilar companies challenge existing patents, which can potentially alter the timeline for market entry [2].
What are the Next Steps for Dupilumab Biosimilar Development?
Companies developing biosimilars must conduct extensive analytical studies, animal studies, and clinical trials to demonstrate that their product is highly similar to the reference product and has no clinically meaningful differences. Once approved, these biosimilars can offer more competitive pricing and treatment options [1].